Vistin Pharma ASA 2024 AR2
The report highlights Vistin Pharma's financial and sustainability performance for the fiscal year 2024. The company achieved a production volume of 5,300 metric tons of Metformin API and finalized a major cooling system investment that reduces VOC emissions by over 95%. Vistin Pharma operates its manufacturing plant in Norway using 100% renewable hydropower, resulting in exceptionally low Scope 1 and Scope 2 emissions. Additionally, the company implemented a freshwater recycling plant that reduces water consumption by 80%.
Company: Vistin Pharma ASA
Sector: Health Care
Country: Norway
Year: 2024
Type: AR2
Pages: 101
Vistin Pharma ASA
Annual Report
The report highlights Vistin Pharma's financial and sustainability performance for the fiscal year 2024. The company achieved a production volume of 5,300 metric tons of Metformin API and finalized a major cooling system investment that reduces VOC emissions by over 95%. Vistin Pharma operates its manufacturing plant in Norway using 100% renewable hydropower, resulting in exceptionally low Scope 1 and Scope 2 emissions. Additionally, the company implemented a freshwater recycling plant that reduces water consumption by 80%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Renewable Energy
Women on Board
Women in Management
Net Zero Target
Employees